MILAN, March 2, 2021 /PRNewswire/ — Innovative Cardiovascular Solutions (ICS), a privately held medical device company developing the most complete comprehensive solution to embolic protection for structural heart and vascular interventions, announced today the success of its first European clinical cases using the next generation of the EMBLOK™ Embolic Protection System in patients […]
Author: Ken Dropiewski
New Analysis of REVERSE Trial Reveals Benefits of CRT for More Patients with Heart Failure
JACC: Clinical Electrophysiology: Findings Highlight Need to Better Classify Heart Failure Outcomes DUBLIN, March 2, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac resynchronization therapy (CRT) for patients with mild heart failure (HF). This new […]
DiA Imaging Analysis partners with Philips to enhance ultrasound with AI-based image quantification
The integration of AI applications within ultrasound technology can help improve access to care. BE’ER SHEVA, Israel, March 2, 2021 /PRNewswire/ — DiA Imaging Analysis Ltd., a leading provider of AI-powered applications for ultrasound, today announced a strategic partnership with Royal Philips, a global leader in health technology, to deliver automated solutions to clinicians at […]
TransMedics Announces Scheduling of OCS Heart FDA Advisory Committee Meeting
ANDOVER, Mass., March 1, 2021 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the FDA’s Office of Health Technology 2 (Cardiovascular Devices) has communicated its intent to hold a Circulatory Systems Device […]
Endotronix Appoints Industry Veteran Dan Dearen to Board of Directors
Expands company’s financial expertise during time of growth in advance of commercial launch LISLE, Ill., March 2, 2021 /PRNewswire/ — Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the appointment of seasoned medical device industry executive Dan Dearen to its Board of […]
Semler Reports Record Fourth Quarter and Year End 2020 Financial Results
2020 HIGHLIGHTS compared to 2019: – Annual revenues increased by 18% – Pre-tax net income of $16.5 million, an increase of $5.8 million, or 54%, compared to $10.7 million – Net income of $14.0 million, a decrease of $1.1 million, or 7%, compared to $15.1 million (which included a $4.4 […]
Acutus Medical Receives Vizient Innovative Technology Contract
Contract Pricing Now Widely Available for the AcQMap® High Resolution 3D Imaging and Mapping System CARLSBAD, Calif., March 02, 2021 (GLOBE NEWSWIRE) — Acutus Medical (Nasdaq: AFIB) today announced that it has received an Innovative Technology contract from Vizient, Inc., the largest, member-driven healthcare performance improvement company in the United States. The […]
Neovasc Comments on Clinical Cardiology Journal Publication
VANCOUVER and MINNEAPOLIS, March 02, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the journal Clinical Cardiology has published an article entitled, “Long-term outcomes of patients undergoing coronary sinus reducer implantation – A multicenter study.” The article, authored by Maayan Konigstein, M.D., Tel […]
FibroGen Provides Regulatory Update on Roxadustat
SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) — FibroGen, Inc. (Nasdaq: FGEN) and its partner, AstraZeneca (LSE/STO/Nasdaq: AZN), today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will hold an advisory committee (AdCom) meeting to review the new drug application for […]
LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich’s Ataxia Gene Therapy Program (LX2006)
LEXEO completes license of all intellectual property rights and pre-clinical data associated with Adverum Biotechnologies’ investigational Friedreich’s ataxia program Pre-clinical research licensed from academic partners and data from Adverum’s program now consolidated to support the advancement of LX2006; Phase 1 clinical trial expected to initiate in 2021 NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) — LEXEO […]



